Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Number of participants with Adverse events (AEs) and Serious Adverse Events (SAEs),Number of participants with AEs and SAEs,Number of participants with clinically significant changes in laboratory values, vital signs,12-lead Electrocardiogram (ECG) and spirometry measurements up to Follow Up,Number of participants with clinically significant changes in laboratory values, vital signs, ECG and spirometry measurements up to Follow Up

This is a two parts study, a single ascending dose followed by 14-days repeat dosing. The
 single ascending dose part will assess two dose levels of GSK3923868 or placebo across two
 treatment periods 1 and 2 in a single cohort of participants with a washout period of a
 minimum of 5 days after each treatment periods. The repeat dose part will assess repeated one
 dose level of GSK3923868 or placebo in treatment period 3 with up to 14 days of follow up in
 the same cohort of participants. The duration of study participation for treatment period 1,
 2 and 3 will be 6, 6 and up to 29 days (including follow up), respectively.